SAN FRANCISCO, Feb. 17, 2011 /PRNewswire/ -- DecisionView Inc., a leading provider of software solutions to optimize clinical trial enrollment for life sciences companies, today announced it more than doubled bookings and clinical trials under contract in 2010. DecisionView's strong results show the industry's growing acceptance of the company's Web-based predictive analytics platform for forecasting, planning, and tracking patient enrollment for clinical trials. To date, DecisionView customers have used the company's flagship StudyOptimizer™ enrollment optimization platform to manage patient enrollment for over 1250 clinical studies with over 450,000 enrolled subjects in 13 therapeutic areas across 91 countries.
"It is gratifying to see DecisionView succeeding and gaining traction in the pharmaceutical industry," said Alex Lancksweert, Director of Performance & Supplier Governance at GlaxoSmithKline. "As an early adopter, we've worked with DecisionView over the years to promote a more robust approach to planning and tracking recruitment of clinical trials. The result has been increased visibility and predictability of patient enrollment."
In addition to strong growth in subscription licenses and contracted clinical trials, 2010 was a very strong year for DecisionView in a number of other areas as well. In 2010, the company:
- Increased penetration to 7 of the top 10 global pharmaceutical companies (up from 4 of the top 10)
- Launched StudyOptimizer 4.2, with innovative new features including historical analysis of enrollment performance, future cost forecasting, and integration with leading enterprise portals
- Drove significant customer adoption of the company's new 4.x platform. The 3.x version of StudyOptimizer will be retired in first half of 2011 when total customer migration will be completed.
- Celebrated award-winning customer deployments, including Pfizer's CIO 100 award
As a result of these successes, DecisionView's board of directors has promoted Linda Drumright to CEO of DecisionView and she has joined the company's board of directors.
"I'm delighted with the progress that DecisionView has made," said Jim Scullion, Executive Chairman of DecisionView. "We are now starting to reap the success of a number of strategic decisions that we made over the past several years, including bringing Linda Drumright into a leadership role in the company. But most importantly, the industry is starting to recognize the value we bring, and several of our customers are doing large-scale enterprise rollouts this year."
DecisionView develops innovative web-based software solutions that enable life sciences organizations around the world to improve clinical trial performance. DecisionView's flagship solution, StudyOptimizer, helps organizations optimize clinical trial enrollment by aggregating patient recruitment data from multiple sources and providing analytics, visualizations, and predictive scenario modeling that delivers unique and actionable insight. StudyOptimizer is used by 7 of the top 10 global pharmaceutical companies, and has been used on over 1,250 clinical studies with over 450,000 subjects enrolled in 13 different therapeutic areas across 91 different countries. Investors in the company include Granite Ventures and Aeris Capital. For additional information about DecisionView, go to http://www.decisionview.com or call 415-538-1800.
SOURCE DecisionView Inc.